The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
Glucagon-Like Peptide-1 is a natural hormone that regulates blood sugar, controls appetite, and slows digestion
The initiative aims to connect startups and tech companies with its business units,
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Subscribe To Our Newsletter & Stay Updated
